Reduced hippocampal glutamate in Alzheimer disease

Rupsingh, Raul; Borrie, Michael; Smith, Morgan; Wells, Jennie; Bartha, Robert

doi:10.1016/j.neurobiolaging.2009.05.002

Cited by 149 publications

(135 citation statements)

References 50 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Reports have indicated that the function of NMDARs decreases in AD, including gene expression (Yashiro and Philpot, 2008), levels of mRNA and protein (Hynd et al, 2001), or neurotransmitters (Rupsingh et al, 2011). A decline in levels of NMDAR subunits has been observed in many AD models and clinical research (Hynd et al, 2004;Mishizen-Eberz et al, 2004;Kravitz et al, 2013), which is consistent with our result that NMDAR1 and NMDAR2B expression decreased in SAMP8 as compared with SAMR1 mice.…”

Section: Hps Treatment Reverses the Changes In Level Of Nmda Subunitssupporting

confidence: 91%

Cognitive-enhancing effects of hydrolysate of polygalasaponin in SAMP8 mice

Wang

et al. 2016

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objectives: The aim of the study is to evaluate the cognitive-enhancing effects of hydrolysate of polygalasaponin (HPS) on senescence accelerate mouse P8 (SAMP8) mice, an effective Alzheimer's disease (AD) model, and to research the relevant mechanisms. Methods: The cognitive-enhancing effects of HPS on SAMP8 mice were assessed using Morris water maze (MWM) and step-through passive avoidance tests. Then N-methyl-D-aspartate (NMDA) receptor subunit expression for both the cortex and hippocampus of mice was observed using Western blotting. Results: HPS (25 and 50 mg/kg) improved the escape rate and decreased the escape latency and time spent in the target quadrant for the SAMP8 mice in the MWM after oral administration of HPS for 10 d. Moreover, it decreased error times in the passive avoidance tests. Western blotting showed that HPS was able to reverse the levels of NMDAR1 and NMDAR2B expression in the cortex or hippocampus of model mice. Conclusions: The present study suggested that HPS can improve cognitive deficits in SAMP8 mice, and this mechanism might be associated with NMDA receptor (NMDAR)-related pathways.

show abstract

Section: Hps Treatment Reverses the Changes In Level Of Nmda Subunitssupporting

confidence: 91%

Cognitive-enhancing effects of hydrolysate of polygalasaponin in SAMP8 mice

Wang

et al. 2016

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

“…AD patients have shown metabolite abnormalities like decreased NAA or NAA/Cr levels [143][144][145][146][147][148][149], elevated mI/Cr ratio [144,147], increased or decreased Cho/Cr ratio levels depending on the stage of the disease [150] and decreased Glu levels [147][148][149] in the gray matter (GM). NAA/mI ratio has been found to be useful for distinguishing between AD patients and healthy subjects.…”

Section: Magnetic Resonance Spectroscopic Imaging (Mrsi)mentioning

confidence: 99%

On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey

Alberdi

Aztiria

Basarab

2016

Artificial Intelligence in Medicine

164

View full text Add to dashboard Cite

“…Soluble Aβ1-42 oligomers are thought to mimic the stimulation of eNMDARs by extracellular glutamate, and disrupt long-term potentiation and synaptic plasticity, eventually leading to synaptic loss [158]. Reports suggest, Aβ induced hyperexcitability is also associated with excessive secretion of glutamate from the neurons and astrocytes, leading to enhanced glutamate levels in the extrasynaptic space [149].…”

Section: Psycho-behavioural Anomalies As Diagnostic Marker For Neurolmentioning

confidence: 99%

Neurochemicals, Behaviours and Psychiatric Perspectives of Neurological Diseases

Choudhury¹,

Sahu²,

Ramanujam³

et al. 2018

Neuropsychiatry

View full text Add to dashboard Cite

Structural changes in different regions of the brain have become clinically relevant and regarded as the signature phenomenon for neurological diseases. Morphological changes in brain are also associated with neuronal and neurochemical alterations. Studies have showed that minute changes in neurochemical levels may have marked impact on the psychobehaviour of the subject. Several neurological disease profiles have been reported with such specific psychobehavioural expression. However, application of behavioural abnormalities as possible disease progress markers has not been considered and emphasised much. Reports suggested that-the subjects, who have already entered into the terminal stage of the disease, used to show cardinal behavioural signs for a specific disease profile. However, psychological expressions are comparatively early expressive. As most of the neurodegenerative disorders are unidirectional and progressive by nature, therapeutic intervention at the right time is essential for attaining the desired outcome. Moreover, early diagnosis can aid in managing the disease progression also. Psychobehavioural analysis could meet the expected outcome of disease diagnosis if implemented properly and timely. In the present review, we have amalgamated the reported behavioural anomalies with the supportive background from neurochemical basis. Further, we have concluded that behaviour centric studies could be a potential diagnostic tool for the early diagnosis of major neurological diseases such as Alzheimer disease, Parkinson's disease, Amyotrophic lateral sclerosis (ALS), Bipolar disorder, Schizophrenia, Impulse control disorder (ICD) and Obsessive-compulsive disorder (OCD).

show abstract

Reduced hippocampal glutamate in Alzheimer disease

Cited by 149 publications

References 50 publications

Cognitive-enhancing effects of hydrolysate of polygalasaponin in SAMP8 mice

Cognitive-enhancing effects of hydrolysate of polygalasaponin in SAMP8 mice

On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey

Neurochemicals, Behaviours and Psychiatric Perspectives of Neurological Diseases

Contact Info

Product

Resources

About